首页 > 最新文献

BMJ Evidence-Based Medicine最新文献

英文 中文
Development of a competency framework for health technology assessment in India. 制定印度卫生技术评估能力框架。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2023-112488
Simon Dixon, Kirti Tyagi, Malkeet Singh, Sitanshu Sekhar Kar, Bhavani Shankara Bagepally, Shankar Prinja, Andrew Booth, Chris Carroll, Aamir Sohail, Abha Mehndiratta
{"title":"Development of a competency framework for health technology assessment in India.","authors":"Simon Dixon, Kirti Tyagi, Malkeet Singh, Sitanshu Sekhar Kar, Bhavani Shankara Bagepally, Shankar Prinja, Andrew Booth, Chris Carroll, Aamir Sohail, Abha Mehndiratta","doi":"10.1136/bmjebm-2023-112488","DOIUrl":"10.1136/bmjebm-2023-112488","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s43-s47"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring progress in institutionalising evidence-informed priority-setting in the Indian healthcare system: an application using the iProSE scale. 衡量印度医疗保健系统在以证据为依据确定优先事项方面的制度化进展情况:使用 iProSE 量表的应用。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2023-112485
Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Sophie Gulliver, Malkeet Singh, Kirti Tyagi, Javier Guzman
{"title":"Measuring progress in institutionalising evidence-informed priority-setting in the Indian healthcare system: an application using the iProSE scale.","authors":"Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Sophie Gulliver, Malkeet Singh, Kirti Tyagi, Javier Guzman","doi":"10.1136/bmjebm-2023-112485","DOIUrl":"10.1136/bmjebm-2023-112485","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s3-s7"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140064786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prioritisation of candidates for HTA: insights from the Indian healthcare landscape. HTA候选人的优先顺序:来自印度医疗保健领域的见解。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2023-112566
Malkeet Singh, Abha Mehndiratta, Manuel Antonio Espinoza, Shankar Prinja, Ursula Giedion
{"title":"Prioritisation of candidates for HTA: insights from the Indian healthcare landscape.","authors":"Malkeet Singh, Abha Mehndiratta, Manuel Antonio Espinoza, Shankar Prinja, Ursula Giedion","doi":"10.1136/bmjebm-2023-112566","DOIUrl":"10.1136/bmjebm-2023-112566","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s8-s10"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing health technology assessment in India: paving the way for sustainable healthcare solutions in developing countries. 在印度利用卫生技术评估:为发展中国家的可持续卫生保健解决方案铺平道路。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2025-113740
Nicolás Meza, Paula Riganti, Kalipso Chalkidou
{"title":"Harnessing health technology assessment in India: paving the way for sustainable healthcare solutions in developing countries.","authors":"Nicolás Meza, Paula Riganti, Kalipso Chalkidou","doi":"10.1136/bmjebm-2025-113740","DOIUrl":"10.1136/bmjebm-2025-113740","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s1-s2"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring adaptive health technology assessment for evaluating 10 cancer interventions: insights and lessons from a pilot study in India. 为评估10项癌症干预措施探索适应性卫生技术评估:来自印度试点研究的见解和教训。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2023-112490
Srobana Ghosh, C S Pramesh, Manju Sengar, Priya Ranganathan, Francis Ruiz, Tabassum Wadasadawala, Prakash Nayak, Jayashree Thorat, Apurva Ashok, Malkeet Singh, Abha Mehndiratta, Cassandra Nemzoff, Hiral Anil Shah

Background: Health technology assessment (HTA) is a valuable tool for informing the efficient allocation of resources in healthcare. However, the resource-intensive nature of HTA can limit its application, especially in low-resource settings. Adapting HTA processes by assessing the available international evidence offers a pragmatic approach to provide evidence for decision-making where resources are constrained.

Objective: This study piloted an adaptive HTA (aHTA) method to evaluate 10 cancer interventions.

Methods: We arranged a joint collaboration with the International Decision Support Initiative and the National Cancer Grid in India to form a working group of clinicians and health economists. We conducted a rapid review of HTA reports and economic evaluations for ten prioritised common cancer interventions for breast, lung, and head and neck cancers. We extracted data on cost-effectiveness, conducted a price benchmarking analysis, estimated treatment costs and calculated the treatment's share of the national insurance family allowance. Finally, we determined through qualitative appraisal whether the intervention would likely to be considered cost-effective in the Indian context.

Results: Of the 10 interventions assessed, 9 had sufficient evidence to make determinations on the likely cost-effectiveness. Three were potentially cost-effective (one after a price discount and another by using the generic price), while five were not, and one was only cost-effective in a subgroup. One intervention required a full HTA due to remaining uncertainty. Information on the likely cost-effectiveness, clinical and safety benefits, and treatment costs was consistently found through publicly available evidence. Assessment methods were modified slightly across the 10 interventions, including expanding the data extraction criteria, updating the calculations and broadening the evidence retrieval.

Conclusion: The aHTA method is a feasible resource-sensitive alternative to traditional HTA for informing decision-making in resource-constrained settings when ample international data on cost-effectiveness for a given topic is available.

背景:卫生技术评估(HTA)是一种有价值的工具,为卫生保健资源的有效分配提供信息。然而,HTA的资源密集型特性限制了其应用,特别是在资源匮乏的环境中。通过评估现有的国际证据来调整HTA程序,是一种务实的方法,可以为资源有限的决策提供证据。目的:本研究采用自适应HTA (aHTA)方法评价10种癌症干预措施。方法:我们安排了与国际决策支持倡议和印度国家癌症网格的联合合作,组成了一个由临床医生和卫生经济学家组成的工作组。我们对HTA报告和对乳腺癌、肺癌和头颈癌的10种优先常见癌症干预措施的经济评估进行了快速回顾。我们提取了有关成本效益的数据,进行了价格基准分析,估计了治疗成本,并计算了治疗在国民保险家庭津贴中的份额。最后,我们通过定性评估确定干预措施在印度的情况下是否可能被认为具有成本效益。结果:在评估的10项干预措施中,9项有足够的证据来确定可能的成本效益。其中三种具有潜在的成本效益(一种经过价格折扣,另一种使用通用价格),而五种没有,一种仅在一个子组中具有成本效益。由于仍然存在不确定性,一项干预需要进行完整的HTA。关于可能的成本效益、临床和安全益处以及治疗费用的信息一直是通过公开证据找到的。评估方法在10个干预措施中略有修改,包括扩展数据提取标准,更新计算和扩大证据检索。结论:aHTA方法是一种可行的资源敏感替代传统的HTA方法,在资源受限的情况下,当一个给定主题的成本效益有充足的国际数据可用时,可以为决策提供信息。
{"title":"Exploring adaptive health technology assessment for evaluating 10 cancer interventions: insights and lessons from a pilot study in India.","authors":"Srobana Ghosh, C S Pramesh, Manju Sengar, Priya Ranganathan, Francis Ruiz, Tabassum Wadasadawala, Prakash Nayak, Jayashree Thorat, Apurva Ashok, Malkeet Singh, Abha Mehndiratta, Cassandra Nemzoff, Hiral Anil Shah","doi":"10.1136/bmjebm-2023-112490","DOIUrl":"10.1136/bmjebm-2023-112490","url":null,"abstract":"<p><strong>Background: </strong>Health technology assessment (HTA) is a valuable tool for informing the efficient allocation of resources in healthcare. However, the resource-intensive nature of HTA can limit its application, especially in low-resource settings. Adapting HTA processes by assessing the available international evidence offers a pragmatic approach to provide evidence for decision-making where resources are constrained.</p><p><strong>Objective: </strong>This study piloted an adaptive HTA (aHTA) method to evaluate 10 cancer interventions.</p><p><strong>Methods: </strong>We arranged a joint collaboration with the International Decision Support Initiative and the National Cancer Grid in India to form a working group of clinicians and health economists. We conducted a rapid review of HTA reports and economic evaluations for ten prioritised common cancer interventions for breast, lung, and head and neck cancers. We extracted data on cost-effectiveness, conducted a price benchmarking analysis, estimated treatment costs and calculated the treatment's share of the national insurance family allowance. Finally, we determined through qualitative appraisal whether the intervention would likely to be considered cost-effective in the Indian context.</p><p><strong>Results: </strong>Of the 10 interventions assessed, 9 had sufficient evidence to make determinations on the likely cost-effectiveness. Three were potentially cost-effective (one after a price discount and another by using the generic price), while five were not, and one was only cost-effective in a subgroup. One intervention required a full HTA due to remaining uncertainty. Information on the likely cost-effectiveness, clinical and safety benefits, and treatment costs was consistently found through publicly available evidence. Assessment methods were modified slightly across the 10 interventions, including expanding the data extraction criteria, updating the calculations and broadening the evidence retrieval.</p><p><strong>Conclusion: </strong>The aHTA method is a feasible resource-sensitive alternative to traditional HTA for informing decision-making in resource-constrained settings when ample international data on cost-effectiveness for a given topic is available.</p>","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s20-s28"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn). 卫生技术评估物有所值吗?估计印度卫生技术评估的投资回报(HTAIn)。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2023-112487
Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, Sophie Gulliver, Hannah Hesselgreaves, Abha Mehndiratta, Francis Ruiz, Kirti Tyagi, Olivia Wu, Javier Guzman, Eleanor Grieve

An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).A framework developed by the University of Glasgow was used to review three 'hta's commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each 'hta'. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.

低收入和中等收入国家对卫生技术评估(HTA)的投资不断增加,使决策者对卫生技术评估的价值和投资回报(ROI)产生了更大的兴趣。然而,很少有研究量化了HTA对卫生系统的价值。本评估旨在量化印度HTA机构(HTAIn)的影响和投资回报率。格拉斯哥大学开发的框架用于审查HTAIn在2018年至2020年期间委托的三个“hta”,并考虑到投资这些过程的机会成本。成本包括维修保养的固定成本及进行每项维修保养的成本。可归属收益是通过从已实现收益中减去反事实收益(在没有HTA的情况下可能实现的收益)来计算的。HTAIn隶属于印度政府卫生和家庭福利部卫生研究司。它的设立是为了促进印度医疗保健领域透明和循证决策的进程。HTA帮助决策者了解备选行动方案的后果,并选择以最低成本产生最佳结果的方案。卫生保健服务的制度化被视为支持全民健康覆盖的关键,这是支持更好地分配有限资源、控制成本和实现健康最大化的一种手段。净健康效益是我们衡量价值的标准。HTAIn的投资回报率是通过汇总可归属收益并将其与投资成本相抵消来计算的。我们的研究结果表明,投资于HTA的回报率为9:1,如果全面实施HTA的建议,这一回报率有可能增加到71:1。不同干预措施与疾病之间ROI的变异性为5:1 ~ 40:1。虽然HTAIn需要财政投资,但它是对资源的有效利用。潜在的更大的影响和干预之间的投资回报率的可变性强调了在HTA中规划实施和良好的主题选择的重要性。
{"title":"Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn).","authors":"Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, Sophie Gulliver, Hannah Hesselgreaves, Abha Mehndiratta, Francis Ruiz, Kirti Tyagi, Olivia Wu, Javier Guzman, Eleanor Grieve","doi":"10.1136/bmjebm-2023-112487","DOIUrl":"10.1136/bmjebm-2023-112487","url":null,"abstract":"<p><p>An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).A framework developed by the University of Glasgow was used to review three 'hta's commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each 'hta'. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.</p>","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s29-s37"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health technology assessment in India in the next decade: reflections on a vision for its path to maturity and impact. 未来十年印度的卫生技术评估:对其走向成熟和产生影响的愿景的思考。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2023-112491
Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Anthony Culyer, Shankar Prinja, Sitanshu Sekhar Kar, Javier Guzman
{"title":"Health technology assessment in India in the next decade: reflections on a vision for its path to maturity and impact.","authors":"Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Anthony Culyer, Shankar Prinja, Sitanshu Sekhar Kar, Javier Guzman","doi":"10.1136/bmjebm-2023-112491","DOIUrl":"10.1136/bmjebm-2023-112491","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s38-s40"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Making an organisation for health technology assessment: lessons from India. 建立卫生技术评估组织:印度的经验教训。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-26 DOI: 10.1136/bmjebm-2023-112484
Victoria Y Fan, Abha Mehndiratta, Jubilee Ahazie
{"title":"Making an organisation for health technology assessment: lessons from India.","authors":"Victoria Y Fan, Abha Mehndiratta, Jubilee Ahazie","doi":"10.1136/bmjebm-2023-112484","DOIUrl":"10.1136/bmjebm-2023-112484","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s41-s42"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A primer to planetary health in evidence-based medicine and clinical decision-making. 地球健康在循证医学和临床决策的入门。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-11-20 DOI: 10.1136/bmjebm-2025-113904
Claudia Cecconi Ebm, Alina Herrmann, Antonio Bognanni, Mehdi Aloosh, Charlotte Michels, Rafael Vieira, Grigorios Leontiadis, Thomas Piggott, Holger J Schuenemann
{"title":"A primer to planetary health in evidence-based medicine and clinical decision-making.","authors":"Claudia Cecconi Ebm, Alina Herrmann, Antonio Bognanni, Mehdi Aloosh, Charlotte Michels, Rafael Vieira, Grigorios Leontiadis, Thomas Piggott, Holger J Schuenemann","doi":"10.1136/bmjebm-2025-113904","DOIUrl":"https://doi.org/10.1136/bmjebm-2025-113904","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reconsidering the role of tramadol in chronic pain management. 重新考虑曲马多在慢性疼痛治疗中的作用。
IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-10-29 DOI: 10.1136/bmjebm-2025-114276
Antonio Alcántara Montero
{"title":"Reconsidering the role of tramadol in chronic pain management.","authors":"Antonio Alcántara Montero","doi":"10.1136/bmjebm-2025-114276","DOIUrl":"https://doi.org/10.1136/bmjebm-2025-114276","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMJ Evidence-Based Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1